Edgewise Therapeutics, Inc. (NASDAQ:EWTX) reported a significant transaction by one of its top executives, according to a recent SEC filing. Behrad Derakhshan, the company's Chief Business Officer, sold 42,068 shares of common stock at prices ranging from $29.00 to $29.28, averaging $29.0276 per share. The total proceeds from the sale amounted to over $1.2 million.
The same filing also disclosed that Derakhshan acquired the same number of shares through an option exercise at a price of $1.93 per share, which totaled approximately $81,191. Following these transactions, Derakhshan's direct ownership in the company stands at 15,121 shares of common stock.
Investors often monitor insider transactions as they provide insights into executives' perspectives on the company's stock value. The sale took place on September 20, 2024, with the filing made public on September 24.
The filing included footnotes indicating that the sale price was an average, with multiple transactions occurring within the specified price range. Additionally, it was noted that the shares acquired included 1,699 shares purchased earlier in May as part of the company's 2021 Employee Stock Purchase Plan.
Edgewise Therapeutics, based in Boulder, Colorado, specializes in pharmaceutical preparations and is known for its focus on innovative treatments in the life sciences sector.
Investors and security holders may request detailed information about the exact number of shares sold at each price point by contacting the reporting person or the company.
"In other recent news, Edgewise Therapeutics has seen promising results from its Phase 1 and Phase 2 trials for its heart disease drug, EDG-7500. The drug demonstrated tolerability and significant reductions in left ventricular outflow tract gradients in patients with Hypertrophic Cardiomyopathy. RBC Capital Markets raised its price target for Edgewise from $32.00 to $42.00, maintaining an Outperform rating, while Truist Securities increased its target from $25.00 to $33.00, keeping a Buy rating. Both firms cited the potential of the company's HCM program as a key factor.
Edgewise has also initiated a new 28-day trial, with initial data expected in the first quarter of 2025. This is part of the company's ongoing development of therapies for severe, rare muscle disorders. Another recent development includes the approval of the 2024 Inducement Equity Incentive Plan, reserving 2 million shares of common stock for new equity awards.
Piper Sandler maintained its Overweight rating on Edgewise, highlighting upcoming milestones such as the Phase 1 trials for EDG-7500. The firm also noted the company's strong financial position and progress in its drug development programs. These recent developments reflect the ongoing efforts of Edgewise to advance its pipeline of innovative therapeutics."
InvestingPro Insights
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) has been under the investor spotlight following a significant insider transaction. The company's market capitalization stands at a robust $2.43 billion, which is indicative of its solid position in the pharmaceutical industry. Despite the recent insider sale, Edgewise Therapeutics holds more cash than debt on its balance sheet, which is a positive signal of financial health and stability. This is a noteworthy InvestingPro Tip, as it suggests that the company has a buffer to fund operations and strategic initiatives.
InvestingPro Data also shows that the company has experienced a significant return over the last week, with a 35.92% increase in its stock price. This trend extends over various periods, with a 34.09% return over the last month and an impressive 337.84% return over the last year. Such performance metrics underscore the stock's strong momentum and might be of particular interest to investors looking for growth opportunities in the biotech sector.
However, potential investors should also be aware that analysts do not anticipate Edgewise Therapeutics will be profitable this year, which is another critical InvestingPro Tip. This insight, coupled with the company's negative earnings metrics such as a P/E Ratio of -17.06 and an operating income of -$136.17 million for the last twelve months as of Q2 2024, could influence investment decisions.
For those seeking further insights, there are additional InvestingPro Tips available on their platform, which can provide a deeper analysis of Edgewise Therapeutics' financials and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.